Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.63 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 3/20 | 0.56 |
| ▸ | GCK | P35557 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | GCKR | Q14397 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23103946 | 0.85 | POLB (0.59) | ALDH1A1SMN1; SMN2POLBGAAGCK | |
| SCHEMBL17646020 | 0.84 | POLB (0.67) | ALDH1A1SMN1; SMN2POLBGAAGCK | |
| SCHEMBL30693019 | 0.81 | POLB (0.72) | ALDH1A1SMN1; SMN2POLBGAALMNA | |
| SCHEMBL31372420 | 0.81 | ALDH1A1 (0.67) | ALDH1A1SMN1; SMN2POLBGAALMNA | |
| SCHEMBL29519879 | 0.81 | ATM (0.55) | ALDH1A1SMN1; SMN2POLBGCKLMNA | |
| SCHEMBL10080556 | 0.81 | ALDH1A1 (0.67) | ALDH1A1SMN1; SMN2POLBGAALMNA | |
| SCHEMBL3149654 | 0.81 | POLB (0.72) | ALDH1A1SMN1; SMN2POLBGAALMNA | |
| SCHEMBL16439685 | 0.81 | MAPT (0.55) | ALDH1A1POLBGAAGCKKDM4E | |
| SCHEMBL28511141 | 0.81 | ATM (0.55) | ALDH1A1SMN1; SMN2POLBGCKLMNA | |
| SCHEMBL23388115 | 0.81 | GAA (0.74) | ALDH1A1SMN1; SMN2POLBGAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250042901-A1 | HETEROARYL CARBOXAMIDE COMPOUNDS AS INHIBITORS OF RIPK2 | BOEHRINGER INGELHEIM INT (DE) | 2025-02-06 | — | — | US | disclosed |
| US-12139484-B2 | Substituted benzamides as RIPK2 inhibitors for treatment of inflammatory bowel disease | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-11-12 | — | — | US | disclosed |
| CN-110023290-B | Heteroaryl carboxamide compounds as RIPK2 inhibitors | 勃林格殷格翰国际有限公司 | 2022-08-12 | — | — | CN | disclosed |
| US-20220081437-A1 | HETEROARYL CARBOXAMIDE COMPOUNDS AS INHIBITORS OF RIPK2 | BOEHRINGER INGELHEIM INT (DE) | 2022-03-17 | — | — | US | disclosed |
| US-11130754-B2 | Substituted benzamides as RIPK2 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-09-28 | — | — | US | disclosed |
| US-11130754-B2 | Substituted benzamides as RIPK2 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-09-28 | — | — | US | disclosed |
| EP-3512833-B1 | HETEROARYL CARBOXAMIDE COMPOUNDS AS INHIBITORS OF RIPK2 | BOEHRINGER INGELHEIM INT (DE) | 2020-07-29 | — | — | EP | disclosed |
| EP-3512833-B1 | HETEROARYL CARBOXAMIDE COMPOUNDS AS INHIBITORS OF RIPK2 | BOEHRINGER INGELHEIM INT (DE) | 2020-07-29 | — | — | EP | disclosed |
| EP-3512833-A1 | HETEROARYL CARBOXAMIDE COMPOUNDS AS INHIBITORS OF RIPK2 | Boehringer Ingelheim International GmbH (DE) | 2019-07-24 | — | — | EP | disclosed |
| US-20190048000-A1 | HETEROARYL CARBOXAMIDE COMPOUNDS AS INHIBITORS OF RIPK2 | BOEHRINGER INGELHEIM INT (DE) | 2019-02-14 | — | — | US | disclosed |
| US-20190048000-A1 | HETEROARYL CARBOXAMIDE COMPOUNDS AS INHIBITORS OF RIPK2 | BOEHRINGER INGELHEIM INT (DE) | 2019-02-14 | — | — | US | disclosed |
| US-10138241-B2 | Substituted benzamides as RIPK2 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-11-27 | — | — | US | disclosed |
| WO-2018052772-A1 | HETEROARYL CARBOXAMIDE COMPOUNDS AS INHIBITORS OF RIPK2 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-03-22 | — | — | WO | disclosed |
| WO-2018052772-A1 | HETEROARYL CARBOXAMIDE COMPOUNDS AS INHIBITORS OF RIPK2 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-03-22 | — | — | WO | disclosed |
| US-20180072717-A1 | HETEROARYL CARBOXAMIDE COMPOUNDS AS INHIBITORS OF RIPK2 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-03-15 | — | — | US | disclosed |
| US-20180072717-A1 | HETEROARYL CARBOXAMIDE COMPOUNDS AS INHIBITORS OF RIPK2 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-03-15 | — | — | US | disclosed |
| US-20180072717-A1 | HETEROARYL CARBOXAMIDE COMPOUNDS AS INHIBITORS OF RIPK2 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190048000-A1 | HETEROARYL CARBOXAMIDE COMPOUNDS AS INHIBITORS OF RIPK2 | RIPK2, RIPK1, RIPK4 | ALDH1A1 4492/4885SMN1; SMN2 2655/4885POLB 2771/4885 |
| US-20180072717-A1 | HETEROARYL CARBOXAMIDE COMPOUNDS AS INHIBITORS OF RIPK2 | RIPK2, RIPK1, RIPK3 | ALDH1A1 4462/4885SMN1; SMN2 2588/4885POLB 2595/4885 |
| US-10138241-B2 | Substituted benzamides as RIPK2 inhibitors | RIPK2, RIPK4, RIPK1 | ALDH1A1 4003/4885SMN1; SMN2 1731/4885POLB 2711/4885 |
| US-20220081437-A1 | HETEROARYL CARBOXAMIDE COMPOUNDS AS INHIBITORS OF RIPK2 | RIPK2, RIPK1, RIPK3 | ALDH1A1 4462/4885SMN1; SMN2 2588/4885POLB 2595/4885 |
| US-11130754-B2 | Substituted benzamides as RIPK2 inhibitors | RIPK2, RIPK4, RIPK1 | ALDH1A1 4003/4885SMN1; SMN2 1731/4885POLB 2711/4885 |
| US-20250042901-A1 | HETEROARYL CARBOXAMIDE COMPOUNDS AS INHIBITORS OF RIPK2 | RIPK2, RIPK1, RIPK4 | ALDH1A1 4492/4885SMN1; SMN2 2655/4885POLB 2771/4885 |
| US-12139484-B2 | Substituted benzamides as RIPK2 inhibitors for treatment of inflammatory bowel disease | RIPK2, RIPK4, RIPK1 | ALDH1A1 3915/4885SMN1; SMN2 2990/4885POLB 3029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.